DxS' TheraScreen Gets Canadian OK | GenomeWeb

NEW YORK (GenomeWeb News) – DxS has received a license from Canadian regulatory authorities to sell its TheraScreen: K-RAS Mutation Kit as a companion diagnostic for Amgen's colorectal cancer therapy panitumumab (Vectibix), the UK-based firm said today.

In addition, Health Canada licensed the assay for broader use as a diagnostic for other anti-EGFR therapies beyond Vectibix.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.